Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2013 | Letter to the Editor

Suggested pathway to assess radiation safety of ¹⁸F-labeled PET tracers for first-in-human studies

Authors: Paolo Zanotti-Fregonara, Adriaan A. Lammertsma, Robert B. Innis

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2013

Excerpt

Dear Sir, …

Available only for authorised users

Zanotti-Fregonara P, Innis RB. Suggested pathway to assess radiation safety of (11)C-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2012;39:544–7.PubMedCrossRef

van der Aart J, Hallett WA, Rabiner EA, Passchier J, Comley RA. Radiation dose estimates for carbon-11-labelled PET tracers. Nucl Med Biol. 2012;39:305–14.PubMedCrossRef

Sakata M, Oda K, Toyohara J, Ishii K, Nariai T, Ishiwata K. Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies. Ann Nucl Med. 2013;27:285–96.PubMedCrossRef

Obrzut SL, Koren AO, Mandelkern MA, Brody AL, Hoh CK, London ED. Whole-body radiation dosimetry of 2-[18F]Fluoro-A-85380 in human PET imaging studies. Nucl Med Biol. 2005;32:869–74.PubMedCrossRef

Bottlaender M, Valette H, Roumenov D, Dolle F, Coulon C, Ottaviani M, et al. Biodistribution and radiation dosimetry of 18F-fluoro-A-85380 in healthy volunteers. J Nucl Med. 2003;44:596–601.PubMed

Kimes AS, Horti AG, London ED, Chefer SI, Contoreggi C, Ernst M, et al. 2-[18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J. 2003;17:1331–3.PubMed

Adler L, Wolodzko J, Stabin M, McNelis T, Gammage L, Joshi A. Radiation dosimetry of F18-AV-45 measured by PET/CT in humans. J Nucl Med. 2008;49 Suppl 1:283.

Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent – a pilot study. Nucl Med Biol. 2010;37:497–508.PubMedCrossRef

Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913–20.PubMedCrossRef

10.

Giussani A, Janzen T, Uusijarvi-Lizana H, Tavola F, Zankl M, Sydoff M, et al. A compartmental model for biokinetics and dosimetry of 18F-choline in prostate cancer patients. J Nucl Med. 2012;53:985–93.PubMedCrossRef

11.

DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002;43:92–6.PubMed

12.

International Commission on Radiological Protection (ICRP). ICRP Publication 106: radiation dose to patients from radiopharmaceuticals—addendum 3 to ICRP publication 53. Ann ICRP. 2008;38 (1–2).

13.

Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, et al. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med. 1998;25:565–74.PubMedCrossRef

14.

International Commission on Radiological Protection (ICRP). ICRP Publication 62: radiological protection in biomedical research. Ann ICRP. 1992;22.

15.

Yaghoubi S, Barrio JR, Dahlbom M, Iyer M, Namavari M, Satyamurthy N, et al. Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med. 2001;42:1225–34.PubMed

16.

Tolvanen T, Lehtio K, Kulmala J, Oikonen V, Eskola O, Bergman J, et al. 18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med. 2002;43:1674–80.PubMed

17.

Doss M, Kolb HC, Zhang JJ, Belanger MJ, Stubbs JB, Stabin MG, et al. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans. J Nucl Med. 2012;53:787–95.PubMedCrossRef

18.

Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med. 2003;44:1482–8.PubMed

19.

Smolarz K, Krause BJ, Graner FP, Wagner FM, Hultsch C, Bacher-Stier C, et al. (S)-4-(3-18F-Fluoropropyl)-L-glutamic acid: an 18F-labeled tumor-specific probe for PET/CT imaging – dosimetry. J Nucl Med. 2013;54:861–6.PubMedCrossRef

20.

Beauregard JM, Croteau E, Ahmed N, van Lier JE, Benard F. Assessment of human biodistribution and dosimetry of 4-fluoro-11beta-methoxy-16alpha-18F-fluoroestradiol using serial whole-body PET/CT. J Nucl Med. 2009;50:100–7.PubMedCrossRef

Title: Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies
Authors: Paolo Zanotti-Fregonara
Adriaan A. Lammertsma
Robert B. Innis
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2512-x

At a glance: The STEP trials

Springer Medicine

Suggested pathway to assess radiation safety of ¹⁸F-labeled PET tracers for first-in-human studies

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2013

A large retrospective single-centre study to define the best image acquisition protocols and interpretation criteria for white blood cell scintigraphy with 99mTc-HMPAO-labelled leucocytes in musculoskeletal infections

Robustness of intratumour 18F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma

Effect of emaciation and obesity on small-animal internal radiation dosimetry for positron-emitting radionuclides

Clinical significance of VEGFR-2 and 18F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy

Freehand SPECT for image-guided sentinel lymph node biopsy in breast cancer

Toxicity of upfront 131I-metaiodobenzylguanidine (131I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis